<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632472</url>
  </required_header>
  <id_info>
    <org_study_id>2015/1507</org_study_id>
    <nct_id>NCT04632472</nct_id>
  </id_info>
  <brief_title>Targeted Left Ventricular Lead Placement, Comparison of Active Fixation Bipolar and Passive Quadripolar Pacemaker Leads</brief_title>
  <official_title>Targeted Left Ventricular Lead Placement for Cardiac Resynchronization Therapy, a Randomized Trial Comparing an Active Fixation Bipolar Left Ventricular Lead and Passive Fixation Quadripolar Leads</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized and patient-blinded trial comparing an active fixation left&#xD;
      ventricular lead with quadripolar passive left ventricular leads. The leads were compared in&#xD;
      order to identify differences in the electrical performance, the ability to achieve a stable&#xD;
      proximal position in a coronary vein located concordant to target segment and clinical&#xD;
      outcome. The patients were followed up for 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized and patient-blinded trial. The objective was to compare an active&#xD;
      fixation left ventricular lead with quadripolar passive left ventricular leads. The left&#xD;
      ventricular segment with latest mechanical activation was identified as target segment by&#xD;
      radial strain speckle-tracking echocardiography.The leads were compared in order to identify&#xD;
      differences in the electrical performance, the ability to achieve a stable proximal position&#xD;
      in a coronary vein located concordant to target segment and clinical outcome. The clinical&#xD;
      outcomes were assessed by echocardiography, change in New York Heart Association (NYHA)&#xD;
      functional class and Minnesota Living With Heart Failure Questionnaire (MLHFQ). The patients&#xD;
      were followed up for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2016</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patient blinded The echocardiographic analyses were done blinded to type of left ventricular lead.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic response</measure>
    <time_frame>Day 0 (baseline). 6 and 12 months after implantation</time_frame>
    <description>Changes in left ventricular end-systolic volume (measured in milliliter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to achieve a position in a coronary vein located concordant to target segment.</measure>
    <time_frame>At implant (day 0)</time_frame>
    <description>The left ventricular lead final position will be compared to the left ventricular target segment. The target segment is determined by radial strain speckle-tracking echocardiography. The lead position is classified as &quot;concordant&quot; or &quot;not concordant&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The left ventricular lead long-axis position.</measure>
    <time_frame>At implant (day 0)</time_frame>
    <description>Measurement of the distance (millimeter) from the active electrode to coronary sinus. Fluoroscopic measurement in a right anterior oblique (RAO) view.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The left ventricular lead pacing threshold</measure>
    <time_frame>Day 0 (baseline). 2, 6 and 12 months after implantation.</time_frame>
    <description>Changes in left ventricular lead pacing capture thresholds, measured in &quot;Volt&quot; with 0.4ms pulse width.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA functional Class</measure>
    <time_frame>Day 0 (baseline). 2, 6 and 12 months after implantation</time_frame>
    <description>Assessment of NYHA functional Class. Class I - No symptoms and no limitation in ordinary physical activity. Class II - Mild symptoms and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms. Class IV - Severe limitations, symptoms even while at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MLHFQ score</measure>
    <time_frame>Day 0 (baseline). 2, 6 and 12 months after implantation</time_frame>
    <description>Evaluating Quality of Life. 21 questions with total scores ranging from 0 to 105. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular lead impedances</measure>
    <time_frame>Day 0 (baseline). 2, 6 and 12 months after implantation</time_frame>
    <description>Changes in left ventricular pacing impedances, measured in &quot;Ohm&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular ejection fraction</measure>
    <time_frame>Day 0 (baseline). 6 and 12 months after implantation.</time_frame>
    <description>Changes in left ventricular ejection fraction (unit:&quot;percent&quot;) measured by echocardiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Active fixation bipolar lead</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Left ventricular bipolar pacemaker lead, fixated by a side helix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Passive fixation quadripolar lead</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Left ventricular quadripolar passive fixation pacemaker lead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy</intervention_name>
    <description>Cardiac resynchronization therapy trial comparing types of leads.</description>
    <arm_group_label>Active fixation bipolar lead</arm_group_label>
    <arm_group_label>Passive fixation quadripolar lead</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) ≤ 35 %&#xD;
&#xD;
          -  NYHA 2-4&#xD;
&#xD;
          -  Electrocardiogram : left bundle branch block (LBBB) and QRS duration &gt;120 ms or&#xD;
             non-LBBB and QRS duration ≥150 ms&#xD;
&#xD;
          -  Optimal medical treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Upgrade procedures due to ventricular pacing&#xD;
&#xD;
          -  No written consensus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Haukeland University Hospital, Department of Heart Disease</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

